United Therapeutics Announces Positive TETON-2 Study Results

United Therapeutics ( (UTHR) ) has shared an update.

On September 2, 2025, United Therapeutics announced positive results from the TETON-2 clinical study of Tyvaso® for idiopathic pulmonary fibrosis (IPF). The study met its primary endpoint, showing significant improvement in forced vital capacity compared to placebo, and demonstrated benefits across various subgroups. These results could potentially reshape IPF treatment and offer new hope for patients, as the company plans to use this data to support a supplemental New Drug Application to the FDA.

The most recent analyst rating on (UTHR) stock is a Buy with a $347.00 price target. To see the full list of analyst forecasts on United Therapeutics stock, see the UTHR Stock Forecast page.

Spark’s Take on UTHR Stock

According to Spark, TipRanks’ AI Analyst, UTHR is a Outperform.

United Therapeutics’ strong financial performance and positive earnings call are the most significant factors driving the stock score. The company’s robust revenue growth, strategic pipeline developments, and share buyback program underscore confidence in future prospects. Technical analysis and valuation also support a favorable outlook, though competitive and regulatory challenges present potential risks.

To see Spark’s full report on UTHR stock, click here.

More about United Therapeutics

United Therapeutics Corporation is a public benefit corporation operating in the biotechnology industry, focusing on developing and commercializing innovative therapies for patients with chronic and life-threatening conditions. Its primary products include Tyvaso, a treatment for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

Average Trading Volume: 647,048

Technical Sentiment Signal: Hold

Current Market Cap: $13.78B

For an in-depth examination of UTHR stock, go to TipRanks’ Overview page.